Equity Profile

CRVS

Corvus Pharmaceuticals, Inc.

Health CareBiotechnology$1.3B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and can influence investor sentiment.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRVS Q2-2026 Earnings Preview

Context

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases. Operating in the health care sector, it aims to address unmet medical needs through its research and development efforts.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-58.69%

Avg Stock Reaction

-2.23%

Last Quarter Recap

In Q1-2026, Corvus reported an EPS of -$0.15, slightly missing expectations. The stock reacted negatively, dropping 5.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Corvus are mixed as the company has struggled to meet earnings estimates in recent quarters. Investors are keenly watching for any signs of improvement.

Bull Case

If Corvus can show better-than-expected clinical trial results or a significant reduction in losses, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide clear updates on its drug pipeline, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on ongoing clinical trials?

Investors will closely monitor trial outcomes, as positive results could significantly impact the company's future and stock price.

How does management plan to address recent earnings misses?

Clear strategies to improve financial performance will be crucial for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Corvus to turn around its clinical trial outcomes, which could lead to a surprise positive reaction.

Supporting Evidence

The options market is pricing a 40.23% move, indicating significant uncertainty that could favor a surprise.

Historically, Corvus has shown a 50% EPS beat rate, suggesting potential for positive surprises.

Recent clinical trial data from peers indicates a favorable environment for new therapies, which could benefit Corvus.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a positive reassessment of the company's prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Corvus can turn around its recent performance and regain investor trust.

Bull Confirmed If

Demonstrating a path to profitability with a reduced EPS loss of less than -$0.10.

Bear Confirmed If

Continuing to report EPS losses greater than -$0.15 without clear plans for improvement.

Pre-Earnings Positioning

Options Market

Implied Move

±40.23%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±40.2% while CRVS has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

96.0%

Calls (48K)P/C Ratio: 0.69Puts (16K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corvus beats expectations, history suggests a potential stock increase of around 2.4%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, as investors await clearer guidance.

Miss

If the company misses again, history suggests a decline of approximately 6.87%, further impacting investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Management's strategy for addressing recent earnings misses.
3Any new partnerships or collaborations that could enhance research capabilities.
4Insights into the company's financial health and cash runway.
5Future guidance on revenue expectations and cost management.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Corvus Pharmaceuticals, Inc. is a biotechnology company focused on developing innovative therapies for cancer and other serious diseases....

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of the company's profitability and can influence investor sentiment.

N/A

Revenue Growth

Revenue growth is crucial for assessing the company's ability to expand its market presence and sustain operations.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

CRVS Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

38%

Avg EPS Surprise

-58.69%

Avg Stock Reaction

-2.23%

Last Quarter Recap

In Q1-2026, Corvus reported an EPS of -$0.15, slightly missing expectations. The stock reacted negatively, dropping 5.57% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Corvus are mixed as the company has struggled to meet earnings estimates in recent quarters. Investors are keenly watching for any signs of improvement.

Bull Case

If Corvus can show better-than-expected clinical trial results or a significant reduction in losses, it could boost investor confidence and lead to a positive stock reaction.

Bear Case

Conversely, if the company continues to miss earnings expectations or fails to provide clear updates on its drug pipeline, it could lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What are the latest updates on ongoing clinical trials?

Investors will closely monitor trial outcomes, as positive results could significantly impact the company's future and stock price.

How does management plan to address recent earnings misses?

Clear strategies to improve financial performance will be crucial for restoring investor confidence.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Corvus to turn around its clinical trial outcomes, which could lead to a surprise positive reaction.

Supporting Evidence

The options market is pricing a 40.23% move, indicating significant uncertainty that could favor a surprise.

Historically, Corvus has shown a 50% EPS beat rate, suggesting potential for positive surprises.

Recent clinical trial data from peers indicates a favorable environment for new therapies, which could benefit Corvus.

Key Risk

If clinical trial results exceed expectations, it could shift the narrative and lead to a positive reassessment of the company's prospects.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's results will be pivotal in determining whether Corvus can turn around its recent performance and regain investor trust.

Bull Confirmed If

Demonstrating a path to profitability with a reduced EPS loss of less than -$0.10.

Bear Confirmed If

Continuing to report EPS losses greater than -$0.15 without clear plans for improvement.

Pre-Earnings Positioning

Options Market

Implied Move

±40.23%

Historical Avg

±5.0%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty around the earnings report.

Options are pricing ±40.2% while CRVS has averaged ±5.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.8%

30d HV

96.0%

Calls (48K)P/C Ratio: 0.69Puts (16K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Corvus beats expectations, history suggests a potential stock increase of around 2.4%, confirming a positive outlook.

In-Line / Cautious

A cautious in-line report may lead to muted reactions, as investors await clearer guidance.

Miss

If the company misses again, history suggests a decline of approximately 6.87%, further impacting investor sentiment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on the status and results of ongoing clinical trials.
2Management's strategy for addressing recent earnings misses.
3Any new partnerships or collaborations that could enhance research capabilities.
4Insights into the company's financial health and cash runway.
5Future guidance on revenue expectations and cost management.